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A Ab bs st tr ra ac ct t
It has been established that heterozygous carriers of ataxia-telangiectasia-causing mutations in the
ATM gene are at approximately two-fold higher risk of breast cancer. Several studies have
attempted to assess the potential implication of the gene’s more common variants in breast
cancer susceptibility. Three large case-control studies have consistently found no evidence of
association for variants with minor allele frequency greater than 5%. Other studies have evaluated
associations for coding variants with intermediate frequency (1-5%), but the results are
inconsistent. Larger and/or combined association studies are needed to clarify this issue.
Ataxia-telangiectasia mutated (ATM) is the gene that under-
lies the rare condition after which it was named. Ataxia-
telangiectasia (A-T) is a neurodegenerative, autosomal
recessive disorder characterized by cerebellar ataxia, telan-
giectases (damaged small blood vessels) in the conjunctiva
and skin, immunological deficiency, hypersensitivity to
ionizing radiation and increased risk of cancer [1]. The
incidence of A-T has been estimated to be between 1 in
40,000 and 1 in 300,000 [2,3]. One of ATM’s most impor-
tant functions is its central role in the repair of DNA double-
strand breaks. Most A-T patients are compound hetero-
zygous carriers of rare mutations in ATM (mutations with a
minor allele frequency [MAF] below 1%), and the vast
majority of these mutations lead to truncation of the protein,
although rare missense mutations that cause A-T have also
been identified.
A possible link between A-T and breast cancer was first
identified over 20 years ago when it was observed that the
relatives of A-T patients had an increased risk of breast
cancer [4]. This association has been confirmed in several
studies since then [5-9], highlighting ATM as a candidate
breast cancer susceptibility gene. Although it seems that
common (MAF over 5%) variants are not associated with
breast cancer risk [10-12], most A-T-causing mutations have
been consistently found to be associated with increased risk,
with heterozygous carriers at approximately twice the risk of
non-carriers [3,7]. What remains unclear is the role of other
ATM variants in breast cancer etiology. A recent study [13]
found an association between non-A-T-causing missense
variants and breast cancer risk, with evidence of a log-linear
increase in risk with the number of such variants carried.
However, a more recent study by Concannon et al. [14]
reported that carrying at least one coding variant (missense
or silent) in ATM was associated with protection from cancer
of the second breast among patients with breast cancer
initially in only one breast (contralateral disease).
A A- -T T- -c ca au us si in ng g   v va ar ri ia an nt ts s   a an nd d   b br re ea as st t   c ca an nc ce er r   r ri is sk k
Studies of the relatives of A-T patients have consistently
suggested that they are at increased risk of breast cancer [6].
Thompson  et al. [7] estimated the risk in heterozygous
carriers of A-T-causing mutations from A-T case families to
be 2.23 times higher (95% confidence interval [CI] = 1.16-4.28)
than that of the general population. Various studies have
attempted to assess this association more directly by
comparing the frequency of specific ATM  mutations in
familial breast cancer cases and controls, but few have
reported conclusive results because of a lack of statistical
power [15-19]. However, a more comprehensive case-control
study of coding and splice-site variants across the entire
gene by Renwick et al. [3] seems to have resolved this issue.
After screening all 62 coding exons and splice junctions in
ATM in 443 index cases from families with at least three
breast cancers and 521 controls, they directly estimated the
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2.37 (95%CI = 1.51-3.78, p = 0.0003) [3]. Subsequent large
studies of additional specific mutations have given consis-
tent results [20,21], further confirming that the ATM muta-
tions that cause A-T are breast cancer susceptibility alleles.
These findings raise the question of whether other ATM
variants also influence breast cancer risk.
A A   r ro ol le e   f fo or r   o ot th he er r   A AT TM M c co od di in ng g   v va ar ri ia an nt ts s? ?
Several case-control studies have evaluated non-A-T-causing
coding variants in ATM  and their association with breast
cancer risk, the majority focusing on missense variants. Such
studies include that of Bretsky et al. [22], who identified 20
germline missense variants in ATM by sequencing cDNA from
274 individuals and then tested these in 428 breast cancer
cases and 426 controls from the Multiethnic Cohort Study.
They found that only two of these variants had MAFs over 5%
and that their allele frequencies were very similar in cases and
controls. Most (17/18) of the remaining missense variants had
MAFs below 1%. No evidence of association with breast cancer
risk was found overall, nor was any found in analyses stratified
by ethnic group. However, the statistical power for such low-
frequency variants was limited, particularly in stratified
analyses, and thus few firm conclusions could be drawn. In
fact, power is a major issue for most studies of these variants
because of their relatively low frequency.
Johnson et al. [13] evaluated nine missense variants in ATM
in a case-control study comprising 473 women with two
primary breast cancers and 2,463 controls. Cases were
selected to increase power to the equivalent of that of a study
of 3,500 unselected cases and 3,500 controls [13]. This was
part of a broader study that included a total of 25 missense
variants in BRCA1,  BRCA2,  ATM,  TP53  and  CHEK2.
Although, individually, only one of the nine ATM variants
considered had an associated unadjusted p-value less than
0.05, there was stronger evidence that the risk of two
primary breast cancers increases with the total number of
variant alleles carried across all 25 SNPs in the five genes.
The estimated odds ratio (OR) per allele was 1.08 (95%CI =
1.02-1.14, p = 0.005). This increased to 1.30 (95%CI = 1.15-1.47,
p = 0.00004) when variants with MAF over 10% were exclu-
ded. For the nine ATM  missense variants (all with MAF
below 10%), the corresponding OR was 1.27 (95%CI = 1.04-1.56,
p = 0.02), corresponding to an estimate OR of 1.13 for a first
primary breast cancer.
Concannon  et al. [14] recently carried out a population-
based study, nested within a cohort study of first primary
invasive breast cancer cases (the WECARE study). They
compared the frequencies of variants in ATM in 708 patients
subsequently diagnosed with contralateral breast cancer
versus 1,397 patients that were never diagnosed with a
second primary breast cancer. A total of 240 variants were
identified by sequencing the coding exons and flanking
intronic regions of the gene in all study participants and then
divided into the categories ‘rare’ and ‘common’ using a cutoff
MAF of 0.5%. Overall, there was weak evidence that carrying
any variant was marginally associated with protection from
contralateral breast cancer (OR = 0.8, 95%CI = 0.7-1.0), and
slightly stronger evidence that this stemmed from the 15
common variants (OR = 0.8, 95%CI = 0.6-0.9, versus OR =
1.0, 95%CI = 0.8-1.4 for rare variants). Of these 15 common
variants, seven were missense changes and eight synony-
mous changes, and only one, rs1801516 (encoding an
Asp1853Gln change), had a MAF greater than 5%. Analysis
of individual variants revealed that all were associated with
ORs of 1.0 or less and four (two missense and two synony-
mous) had unadjusted p-values less than 0.05. The two
missense variants were rs1800057 (Pro1054Arg) and
rs1801673 (Asp1853Val).
The finding of Concannon et al. [14] for the individual
missense variant Pro1054Arg is consistent with non-
significant results reported in smaller studies [11,22,23],
suggesting a possible protective effect against both first
primary breast cancer and a second contralateral cancer.
However, Johnson et al. [13] estimated an OR of 1.30
(95%CI = 1.05-1.58) for a first primary breast cancer associa-
ted with this variant. Furthermore, several other case-
control studies have reported ORs greater than 1.0 for
individual missense variants with frequency greater than
0.5%. Johnson et al. [13] reported an OR of 1.19 (95%CI =
0.72-1.83) for Asp1853Val, and ORs of 1.23 (95%CI =
0.89-1.66) and 1.11 (95%CI = 0.84-1.43) for two other
missense variants with MAFs over 0.5%; such associations
were not observed in the WECARE study. Similarly, the
study by Bretsky et al. [22] reports an individual increased
risk-association for a third additional such variant (OR =
2.36, 95%CI = 0.84-7.58). Renwick et al. [3] found no
overall association between 35 detected non-A-T-associated
missense variants and familial breast cancer, but variant-
specific analysis gave ORs ranging from 0.49 (95%CI =
0.20-1.14) to 1.50 (95%CI = 0.79-2.89) for those with a MAF
over 0.5%. Results from other studies of specific missense
variants have also been mixed [24,25].
It remains unclear how to interpret these findings for coding
variants. The overall results of Concannon et al. [14] and
Johnson  et al. [13] are essentially contradictory, although
neither found statistically conclusive evidence either way. It
therefore seems that larger sample sizes are required to
clarify the role of non-A-T-causing coding variants in ATM
in breast cancer susceptibility, in terms of both variant-
specific effects and whether they act in a consistent direction
and/or act in a log-additive manner.
A A   r ro ol le e   f fo or r   c co om mm mo on n   p po ol ly ym mo or rp ph hi is sm ms s? ?
Common variations in ATM have been assessed by various
studies in relation to breast cancer risk by comparing the
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MAF over 5% in cases and controls. Two large studies (over
1,000 cases) have evaluated selected SNPs and found no
evidence of association [26,27]. A Korean study [28] of five
SNPs in ATM, comprising 996 cases and 1,181 controls,
found some evidence both of individual dominant effects for
three SNPs (0.005 < p-value < 0.05) and of differences in
the distribution of haplotypes formed by all five SNPs.
However, this finding has not been replicated. In fact, three
larger case-control studies of tag-SNPs selected to cover
common variation across the entire gene have consistently
found no evidence of association [10-12]. Tamimi et al. [12]
studied five haplotype-tagging SNPs in 1,309 cases and 1,761
controls from the Nurses’ Health Study, whereas Einars-
dóttir  et al. [11] studied seven haplotype-tagging SNPs in
1,579 cases and 1,516 controls from Sweden. In the largest
related study to date, Baynes et al. [10] evaluated nine tag-
SNPs in ATM in 2,278 cases and 2,180 controls from the UK.
Although it is possible that gene-environment interaction or
other factors might explain different main effects across
countries, the balance of evidence suggests that common
variants in ATM  are not associated with increased breast
cancer risk.
C Co on nc cl lu us si io on ns s
In summary, rare A-T-causing mutations in the ATM gene
are associated with a two-fold increased risk of breast cancer
relative to the general population. Common polymorphisms
do not seem to be associated with susceptibility to the
disease, at least in populations of European origin. The role
of rare non-A-T-causing coding variants is less clear and
statistical power is a limiting factor for most studies. The
results from studies so far are inconclusive and inconsistent.
Further, large and/or combined association studies are
needed to adequately address this issue.
A Ab bb br re ev vi ia at ti io on ns s
A-T, ataxia-telangiectasia; ATM, ataxia-telangiectasia mutated;
CI, confidence interval; MAF, minor allele frequency; OR,
odds ratio; SNP, single nucleotide polymorphism.
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